Tagged with

USA Glenn Robertelli, CEO of RI Bio, is shaping Rhode Island into a rising life sciences hub through strategic partnerships, innovative programs, and support for early-stage biotech. Despite the state’s small size, Rhode Island ranks fourth nationally in NIH funding and is a top ten leader in bioscience patents and medical…

Hong Kong Nearly two years on from our last conversation with Henry Yau, Hong Kong’s clinical trials narrative has shifted from institutional intent to operational execution. The managing director of the HKU Clinical Trials Centre reflects on how regulatory reform, ecosystem coordination, and on-the-ground capability are now aligning, repositioning clinical research as…

USA At a moment when rare disease policy, diagnostics, and patient-driven research are converging, Danielle Carnival sets out a clear vision for the role of the Undiagnosed Diseases Network Foundation. Drawing on her experience across neuroscience, federal health policy, and patient-led organisations, she explains how UDNF operates upstream of diagnosis, addressing…

France Denmark and France are intensifying their cooperation in life sciences at a time when resilience, innovation and industrial capacity have become strategic priorities for Europe. In this interview, Hanne Fugl Eskjær, Denmark’s Ambassador to France, reflects on how complementary strengths in research, digital health and public-private collaboration are shaping a…

USA Genome editing is moving from proof of concept to clinical reality, but questions around scale, cost, and responsibility now define its future. In this interview, Brad Ringeisen outlines how the Innovative Genomics Institute is shaping CRISPR as a platform for real-world impact, bridging philanthropy, academia, and industry while navigating regulation,…

MEA Rare diseases in the Middle East and Africa are no longer an afterthought. As regulatory frameworks mature and governments demand deeper partnership, access, science and local commitment are being redefined. In this interview, Sherif Basha explains how Versalya Pharma is building a rare diseases platform designed for long-term impact, translating…

USA The United States sits at a turning point in allergy care, shaped by decades of legacy practice and a growing demand for disease-modifying solutions. In this conversation, Peter Halling outlines how ALK navigates structural complexity, builds local scale, and prepares its next wave of innovation across immunotherapy and anaphylaxis. The…

USA North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the combination of large-scale capacity, experienced talent, and a tightly integrated site network is shaping a long-term manufacturing platform designed for…

Global ISPOR’s Rob Abbott traces AI’s evolution in healthcare from early expert systems to today’s machine learning and large language models, arguing that AI is now central to health economics and outcomes research (HEOR) and healthcare decision-making. Abbott highlights concrete use cases in genomics, evidence synthesis, and medical imaging, while stressing…

Global Bristol Myers Squibb (BMS), faced with patent expiries for its two largest historical revenue-generators, is racing to replace them. The US giant is re-entering the hot-again neuroscience space, as well as bringing forward cardiovascular, immunology, and oncology molecules, with management proclaiming that six of its pipeline assets boast multibillion-dollar potential.…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include WuXi XDC’s acquisition of TOT Biopharm to expand ADC CDMO capabilities, Sino Biopharma’s entry into RNAi therapeutics with the acquisition of Hygieia, and RemeGen’s US$ 5.6 billion licensing deal with AbbVie. IPO filings by Exegenesis, Immvira, and Genhouse Bio,…

Taiwan With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a biologic therapy worldwide. Now CEO, Chang has overseen the company’s evolution from a single-asset HIV specialist to a globally recognised…